Bicuspid Aortic ValveIRM-BAONCT03474159
Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve by Multimodal Imaging
A study testing Magnetic Resonance Imaging, Transthoracic echocardiography and Echography UltraFast in people with Bicuspid Aortic Valve, run by French Cardiology Society at 1 site in France.
Trial summary
The objective is the development and validation of morphological markers informative of aortic dilatation in order to improve the precision of the risk of aneurysm of the thoracic aorta and of acute aortic syndrome for patients with bicuspid aortic valve (BAV). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bicuspid Aortic Valve
- What is being tested?
- Magnetic Resonance Imaging, Transthoracic echocardiography and Echography UltraFast
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 7 Nov 2018to 24 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults over 18 years of age,
- confirmed BAV by TTE computed tomography or MRI.
- Adults benefiting from a social security scheme,
- having received information on the research
- having signed the consent form
Who cannot join
- Patient with a syndromic form of BAV:
- Loeys-Dietz syndrome,
- Turner syndrome
- Williams-Beuren syndrome
- Shone syndrome
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve (BAV) by Multimodal Imaging (MRI, Echocardiography and Ultrafast Ultrasound Imaging)
The objective is the development and validation of morphological markers informative of aortic dilatation in order to improve the precision of the risk of aneurysm of the thoracic aorta and of acute aortic syndrome for patients with bicuspid aortic valve (BAV).
The primary objective of this study is to demonstrate a correlation between the aortic local pulse wave velocity (PWV) measured with MRI and the progression of the thoracic aorta diameters measured by MRI after a follow-up of 2 years.
Read the detailed description
Background Bicuspid Aortic Valve (BAV) is the most common congenital heart defect with prevalence around 1 to 2% of the general population . It is defined by the presence of two functional cusps with less than three parallel zones of apposition between the cusps. This different valve's morphology is associated with a spectrum of valvular (aortic stenosis and insufficiency) and aortic complications (aneurysm and dissection). Indeed, the valvular abnormality is associated with changes in the aortic arch with an increase in the incidence of ascending aortic aneurysm unrelated to valvular functional impairment. The mechanisms responsible for aortic involvement are still incompletely understood but combine, in varying proportions, a constitutional fragility (linked to a common embryological origin of the aortic valve and the aortic arch) and to the haemodynamic modifications, generated by the specific morphology of BAV .
Current risk prediction of aneurysm development is currently performed only with the ascending aortic diameter, associated with history of aortic coarctation and familial history of dissection. Moreover, aortic dilatation may occur after aortic valve replacement alone, necessitating a second intervention, with a higher surgical risk. Improvement of the aortopathy evaluation is therefore a major stake in the evaluation of the BAV patient.
Studies of the biomechanical properties of the BAV aortic wall converge towards an increase in arterial stiffness as well as in other elastopathies such as Marfan's disease. Thus, measurements of aortic distensibility in trans-thoracic echocardiography (TTE) or MRI, or the measurement of the Pulse Wave Velocity (PWV) are significantly different case of BAV compared to the general population. However, no prospective study has demonstrated the prognostic role of these morphological biomarkers in the prediction of aortic dilation.
From a biomechanical point of view, the vessel's rupture appears when the mechanical stress applied to the wall exceeds the material resistance properties. The aortic resistance evaluation requires the use of different imaging modalities which propose the measurement of stiffness parameters. Circumferential stiffness (with TTE or MRI) can be evaluated by measuring the distensibility. In addition, longitudinal stiffness can be evaluated by measuring the local PWV.
We aim at better defining the vascular involvement of BAV patients by determining the prognostic role of functional parameters as non-invasive predictive factors for aortic dilation.
Hypothesis:
1.Main hypothesis The main hypothesis is that the progression of aortic dilation is dependent on the longitudinal and circumferential aortic stiffness in case of BAV.
The investigators will therefore try to demonstrate a correlation between the local PWV measurements in MRI, combined with a simultaneous measurement of the non-invasive central pressure (SphygmoCor XCEL®, Atcor Medical ©), with the segmental aortic size progression. The investigators hope to define new biomarkers aortic dilation prediction.
1.Secondary hypothesis
- The measurement of the local PWV of the common carotid artery, measured with UF, is correlated with the progression of the aortic dilation.
- The measurement of aortic distensibility at the Valsalva sinus and ascending tubular aortic levels, measured in TTE or MRI, correlates with the progression of aortic dilation.
Originality and innovative aspects - Prospective evaluation of the different aortic segments dilatation in case of BAV: Few studies have prospectively evaluated the aortic dilation progression in BAV. There are currently no prognostic markers of dilatation validated in this group.
- Use of aortic MRI combined with central pressure measurement as a prognostic evaluation tool for aortopathy associated with BAV: Following the development of 4D MRI in cardiovascular imaging, evaluation of the aorta is possible by studying both the wall's movements during the cardiac cycle and the wall shear stress evaluation. This makes possible to obtain, at each part of the thoracic aorta, measures of circumferential distensibility, local PWV, and shear stress.
Coupling these two imaging modalities is particularly interesting in the aortic evaluation of BAV due to the involvement of the flow changes in aortic stiffness.
- Use of the common carotid artery stiffness as a prognostic evaluation tool for aortopathy associated with BAV independently of the aortic diameter Due to the common embryological origin of aorta and the common carotid arteries, aortopathy associated with BAV is associated with an increase in of the common carotid arteries stiffness.
The evaluation of the carotid artery will therefore help to evaluate the correlation between carotid rigidity and progression of aortic dilation.
- Evaluation of the local PWV as carotid stiffness biomarker Ultrasound analysis will also be innovative, with the use of a fine ultrasonic method with very high frame rate (more than 10,000 images per second) developed by the Langevin Institute (Mathias Fink, Michael Tanter and Mathieu Pernot). The collaboration between the Langevin Institute and the H.E.G. lead to numerous publications both in the vascular and cardiac levels. The vascular medicine department has an Aixplorer® prototype with vascular and cardiac applications on site. The advantage of this technology is its ultrafastecho mode with very high temporal resolution which allows the vascular level to visualize and to calculate the speed of the arterial pulse wave which is correlated to the local rigidity.
The use of this innovative technique in aortic bicuspid will hopefully validate the evaluation of the carotid velocity of the pulse wave as an easily accessible prognostic marker of aortic dilation.
Purpose of the research
The objective is the development and validation of morphological markers informative of aortic dilatation in order to improve the precision of the risk of aneurysm of the thoracic aorta and of acute aortic syndrome for patients with BAV.
The primary objective of this study is to demonstrate a correlation between the aortic local PWV measured with MRI and the progression of the thoracic aorta diameters measured by MRI after a follow-up of 2 years
The secondary objectives are:
- To demonstrate a correlation between the progression of the dilatation of the different segments of the thoracic aorta with the following measures:
- Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level.
- Aortic distensibility measured in TTE of the same segments in TM and in B mode .
- Carotid pulse rate measured on carotid arteries by UF.
- To demonstrate a correlation between the progression of the dilatation of the different segments of the thoracic aorta with the following environmental risk factors:
- Active Smoking
- Diabetes
- Hypertension
- Familial form of aortic BAV (defined by the presence of a relative, 1st or 2nd degree, with BAV or thoracic aortic aneurysm)
- Morphological type of BAV
- Aortic coarctation
- Conditions
- Bicuspid Aortic Valve
- Being tested
- Magnetic Resonance Imaging, Transthoracic echocardiography, Echography UltraFast
- Keywords
- Bicuspid aortic valve, aortic aneurysm, stiffness, Pulse wave velocity
- Medical subject headings
- Bicuspid Aortic Valve Disease, Aortic Aneurysm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic Resonance ImagingDevice
Also called MRI
Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
Transthoracic echocardiographyDevice
Also called TTE
Aortic distensibility measured in TTE of the same segments in TM and in B mode
Echography UltraFastDevice
Also called UF
Carotid pulse rate measured on carotid arteries by UF
| Study group | Role | What they receive |
|---|---|---|
| patients | Other | patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF Receives: Device: Magnetic Resonance Imaging; Device: Transthoracic echocardiography; Device: Echography UltraFast |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of the progression of artic dilation with MRI
The measure evaluates a change, which is why there is more than one time point. For patients, a first MRI and a second MRI will be performed after 2 years (+/- 2 months) in order to evaluate prospectively the progression of aortic dilatation according to stiffness parameters.
Measured: For each patient, inclusion in the study will be associated with one-day hospitalization with: MRI (=first MRI), TTE and UF (at T0). Patients will then be re-examined after 2 years to perform a second MRI to assess aortic dilatation (T=2 years).
Secondary outcomes (1)
Comparison of aortic stiffness evaluation with different methods TTE, MRI, UF
Comparison of aortic stiffness evaluation with different methods TTE, MRI, UF
Measured: For each patient, inclusion in the study will be associated with one-day hospitalization with: MRI (=first MRI), TTE and UF (at T0). Patients will then be re-examined after 2 years to perform a second MRI to assess aortic dilatation (T=2 years).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2018
- Study start7 Nov 2018
- Primary completion24 Sep 2024
- Study completion24 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bicuspid Aortic ValveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- French Cardiology Society
- Sponsor type
- University, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France, Centre National de la Recherche Scientifique, France
- Responsible party
- Sponsor
- Investigators
- Emmanuel MESSAS, Principal investigator, APHP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03474159
- Sponsor's protocol ID
- 2016-08
- Acronym
- IRM-BAO
- Status last verified
- Feb 2025
- First submitted
- 23 Feb 2018
- Last updated
- 14 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve (BAV) by Multimodal Imaging (MRI, Echocardiography and Ultrafast Ultrasound Imaging)
- ClinicalTrials.gov ID
- NCT03474159
- Acronym / sponsor ID
- IRM-BAO / 2016-08
- Conditions
- Bicuspid Aortic Valve
- Keywords
- Bicuspid aortic valve, aortic aneurysm, stiffness, Pulse wave velocity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- French Cardiology SocietyUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France, Centre National de la Recherche Scientifique, France
- Study start
- 7 Nov 2018 (actual)
- Primary completion
- 24 Sep 2024 (actual)
- Study completion
- 24 Sep 2024 (actual)
- First posted
- 22 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective is the development and validation of morphological markers informative of aortic dilatation in order to improve the precision of the risk of aneurysm of the thoracic aorta and of acute aortic syndrome for patients with bicuspid aortic valve (BAV).
The primary objective of this study is to demonstrate a correlation between the aortic local pulse wave velocity (PWV) measured with MRI and the progression of the thoracic aorta diameters measured by MRI after a follow-up of 2 years.
Detailed description
Background Bicuspid Aortic Valve (BAV) is the most common congenital heart defect with prevalence around 1 to 2% of the general population . It is defined by the presence of two functional cusps with less than three parallel zones of apposition between the cusps. This different valve's morphology is associated with a spectrum of valvular (aortic stenosis and insufficiency) and aortic complications (aneurysm and dissection). Indeed, the valvular abnormality is associated with changes in the aortic arch with an increase in the incidence of ascending aortic aneurysm unrelated to valvular functional impairment. The mechanisms responsible for aortic involvement are still incompletely understood but combine, in varying proportions, a constitutional fragility (linked to a common embryological origin of the aortic valve and the aortic arch) and to the haemodynamic modifications, generated by the specific morphology of BAV .
Current risk prediction of aneurysm development is currently performed only with the ascending aortic diameter, associated with history of aortic coarctation and familial history of dissection. Moreover, aortic dilatation may occur after aortic valve replacement alone, necessitating a second intervention, with a higher surgical risk. Improvement of the aortopathy evaluation is therefore a major stake in the evaluation of the BAV patient.
Studies of the biomechanical properties of the BAV aortic wall converge towards an increase in arterial stiffness as well as in other elastopathies such as Marfan's disease. Thus, measurements of aortic distensibility in trans-thoracic echocardiography (TTE) or MRI, or the measurement of the Pulse Wave Velocity (PWV) are significantly different case of BAV compared to the general population. However, no prospective study has demonstrated the prognostic role of these morphological biomarkers in the prediction of aortic dilation.
From a biomechanical point of view, the vessel's rupture appears when the mechanical stress applied to the wall exceeds the material resistance properties. The aortic resistance evaluation requires the use of different imaging modalities which propose the measurement of stiffness parameters. Circumferential stiffness (with TTE or MRI) can be evaluated by measuring the distensibility. In addition, longitudinal stiffness can be evaluated by measuring the local PWV.
We aim at better defining the vascular involvement of BAV patients by determining the prognostic role of functional parameters as non-invasive predictive factors for aortic dilation.
Hypothesis:
1.Main hypothesis The main hypothesis is that the progression of aortic dilation is dependent on the longitudinal and circumferential aortic stiffness in case of BAV.
The investigators will therefore try to demonstrate a correlation between the local PWV measurements in MRI, combined with a simultaneous measurement of the non-invasive central pressure (SphygmoCor XCEL®, Atcor Medical ©), with the segmental aortic size progression. The investigators hope to define new biomarkers aortic dilation prediction.
1.Secondary hypothesis
- The measurement of the local PWV of the common carotid artery, measured with UF, is correlated with the progression of the aortic dilation.
- The measurement of aortic distensibility at the Valsalva sinus and ascending tubular aortic levels, measured in TTE or MRI, correlates with the progression of aortic dilation.
Originality and innovative aspects - Prospective evaluation of the different aortic segments dilatation in case of BAV: Few studies have prospectively evaluated the aortic dilation progression in BAV. There are currently no prognostic markers of dilatation validated in this group.
- Use of aortic MRI combined with central pressure measurement as a prognostic evaluation tool for aortopathy associated with BAV: Following the development of 4D MRI in cardiovascular imaging, evaluation of the aorta is possible by studying both the wall's movements during the cardiac cycle and the wall shear stress evaluation. This makes possible to obtain, at each part of the thoracic aorta, measures of circumferential distensibility, local PWV, and shear stress.
Coupling these two imaging modalities is particularly interesting in the aortic evaluation of BAV due to the involvement of the flow changes in aortic stiffness.
- Use of the common carotid artery stiffness as a prognostic evaluation tool for aortopathy associated with BAV independently of the aortic diameter Due to the common embryological origin of aorta and the common carotid arteries, aortopathy associated with BAV is associated with an increase in of the common carotid arteries stiffness.
The evaluation of the carotid artery will therefore help to evaluate the correlation between carotid rigidity and progression of aortic dilation.
- Evaluation of the local PWV as carotid stiffness biomarker Ultrasound analysis will also be innovative, with the use of a fine ultrasonic method with very high frame rate (more than 10,000 images per second) developed by the Langevin Institute (Mathias Fink, Michael Tanter and Mathieu Pernot). The collaboration between the Langevin Institute and the H.E.G. lead to numerous publications both in the vascular and cardiac levels. The vascular medicine department has an Aixplorer® prototype with vascular and cardiac applications on site. The advantage of this technology is its ultrafastecho mode with very high temporal resolution which allows the vascular level to visualize and to calculate the speed of the arterial pulse wave which is correlated to the local rigidity.
The use of this innovative technique in aortic bicuspid will hopefully validate the evaluation of the carotid velocity of the pulse wave as an easily accessible prognostic marker of aortic dilation.
Purpose of the research
The objective is the development and validation of morphological markers informative of aortic dilatation in order to improve the precision of the risk of aneurysm of the thoracic aorta and of acute aortic syndrome for patients with BAV.
The primary objective of this study is to demonstrate a correlation between the aortic local PWV measured with MRI and the progression of the thoracic aorta diameters measured by MRI after a follow-up of 2 years
The secondary objectives are:
- To demonstrate a correlation between the progression of the dilatation of the different segments of the thoracic aorta with the following measures:
- Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level.
- Aortic distensibility measured in TTE of the same segments in TM and in B mode .
- Carotid pulse rate measured on carotid arteries by UF.
- To demonstrate a correlation between the progression of the dilatation of the different segments of the thoracic aorta with the following environmental risk factors:
- Active Smoking
- Diabetes
- Hypertension
- Familial form of aortic BAV (defined by the presence of a relative, 1st or 2nd degree, with BAV or thoracic aortic aneurysm)
- Morphological type of BAV
- Aortic coarctation
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients | Other | Device: Magnetic Resonance Imaging, Device: Transthoracic echocardiography, Device: Echography UltraFastpatients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults over 18 years of age,
- confirmed BAV by TTE computed tomography or MRI.
- Adults benefiting from a social security scheme,
- having received information on the research
- having signed the consent form
Key exclusion criteria (5 listed)
- Patient with a syndromic form of BAV:
- Loeys-Dietz syndrome,
- Turner syndrome
- Williams-Beuren syndrome
- Shone syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic Resonance ImagingAlso: MRIAortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level | Device | patients |
| Transthoracic echocardiographyAlso: TTEAortic distensibility measured in TTE of the same segments in TM and in B mode | Device | patients |
| Echography UltraFastAlso: UFCarotid pulse rate measured on carotid arteries by UF | Device | patients |
Primary outcome
Evaluation of the progression of artic dilation with MRI
Time frame: For each patient, inclusion in the study will be associated with one-day hospitalization with: MRI (=first MRI), TTE and UF (at T0). Patients will then be re-examined after 2 years to perform a second MRI to assess aortic dilatation (T=2 years).
The measure evaluates a change, which is why there is more than one time point. For patients, a first MRI and a second MRI will be performed after 2 years (+/- 2 months) in order to evaluate prospectively the progression of aortic dilatation according to stiffness parameters.
1 secondary outcome
Comparison of aortic stiffness evaluation with different methods TTE, MRI, UF
Time frame: For each patient, inclusion in the study will be associated with one-day hospitalization with: MRI (=first MRI), TTE and UF (at T0). Patients will then be re-examined after 2 years to perform a second MRI to assess aortic dilatation (T=2 years).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Bicuspid Aortic Valve
Active, not recruiting
Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
Aortic Stenosis With Bicuspid Valve
Enrolling by invitationObservational study
Bicuspid Aortic Valve (BAV) Registry
Bicuspid Aortic Valve
Recruiting
TAVR vs SAVR in Severe Bicuspid Aortic Stenosis
Bicuspid Aortic Valve Disease
RecruitingObservational study
Nordic Consortium for Acute Type A Aortic Dissection-2
Aortic Dissection
RecruitingObservational study
A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm
Aortic Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emmanuel MESSAS principal investigator
APHP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnetic Resonance Imaging, Transthoracic echocardiography and Echography UltraFast in people with Bicuspid Aortic Valve, run by French Cardiology Society at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of the progression of artic dilation with MRI (time frame: For each patient, inclusion in the study will be associated with one-day hospitalization with: MRI (=first MRI), TTE and UF (at T0). Patients will then be re-examined after 2 years to perform a second MRI to assess aortic dilatation (T=2 years).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2025.